Targeting the hepatic adropin signaling pathway in obesity
Targeting the hepatic adropin signaling pathway in obesity
批准号:
10677279
负责人:
Bellina Mushala
金额:
$4.32万
依托单位国家:
美国
项目类别:
财政年份:
2023
资助国家:
美国
项目状态:
已结题
起止时间:
2023-04-01 至 2024-01-31
关键词:
AddressAnimal ModelApoptosisAtherosclerosisBiochemicalBioenergeticsBiological ProcessBrainCardiacCell membraneCellsComplexCoronary ArteriosclerosisDefectDevelopmentDiabetes MellitusDietDiseaseDisease ProgressionEducationEndotheliumEnergy Metabolism PathwayEnzymesEssential GenesExhibitsFatty AcidsFatty LiverFatty acid glycerol estersFellowshipFibrosisG-Protein-Coupled ReceptorsGenetic DiseasesGlucoseGoalsHeartHepaticHepatocyteHistologicHomeostasisImmunohistochemistryImpairmentIn VitroInflammationInflammatory ResponseKnock-outKnockout MiceLigandsLinkLipidsLiverMeasuresMediatingMediatorMetabolicMetabolic DiseasesMetabolismMolecularNull LymphocytesNutrientNutrition DisordersObesityObesity associated diseaseObesity associated liver diseaseOrphanPPAR gammaPathologicPathologyPeripheralPhenotypePopulationPrevalenceRecombinantsRegulationRegulatory PathwayResearchResistanceRisk FactorsRoleSignal PathwaySignal TransductionTechniquesTestingTherapeutic EffectTissuesTrainingUnited StatesUp-RegulationWestern BlottingWild Type Mouseblood glucose regulationcareerdesigndiabeticeffective therapyhuman subjectin vivolipid metabolismliver developmentliver injurymouse modelnon-alcoholic fatty liver diseasenonalcoholic steatohepatitisnoveloxidationoxidative damagepeptide hormonepreventable deathprotective effectreceptorresponseuptake
中文摘要
项目摘要/摘要
在美国,肥胖是可预防死亡的第二大原因。肥胖是一种复杂的营养问题
以及由能量不平衡驱动的遗传性疾病,是各种疾病的基本风险因素
病理包括冠状动脉疾病、糖尿病、非酒精性脂肪性肝病和动脉粥样硬化。
在不同组织中导致肥胖相关疾病的细胞和分子机制还不完全清楚。
这对开发有效和高效的治疗方法构成了障碍。阿洛平
是一种新近鉴定的肝脏和大脑衍生的多肽激素,对燃料有强大的作用
外周组织中的底物代谢。肥胖症和糖尿病患者肾上腺素水平显著降低
这种下降与肥胖增加和葡萄糖稳态受损有关。
此外,肾上腺素缺乏与肝脏肥胖症的发生有关。
例如NAFLD和NASH。在这个团契申请中,我们将确定分子信号通路
了解肾上腺素在肝脏燃料代谢中的作用,并探讨其对NAFLD和
纳什。在目标1中,我们将确定肾上腺素如何与细胞膜受体GPR19结合来调节
肝细胞燃料代谢。在目标2中,我们将确定GPR19是否为保护作用所必需的
阿屈平抗肝损伤。通过结合尖端的新陈代谢技术和全面的培训
计划,这笔奖学金将使我为代谢研究和科学研究的下一阶段做准备
教育。
英文摘要
PROJECT SUMMARY/ABSTRACT
Obesity is the second leading cause of preventable death in the United States. Obesity is a complex nutritional
and genetic disorder that is driven by energy imbalances, and serves as a fundamental risk factor in various
pathologies including coronary artery disease, diabetes, non-alcoholic fatty liver disease, and atherosclerosis.
The cellular and molecular mechanisms that drive obesity-related disease in different tissues are not fully
elucidated, and this represents an impediment to the development of effective and efficient treatments. Adropin
is a recently characterized liver- and brain-derived peptide hormone that exerts powerful effects on fuel
substrate metabolism in peripheral tissues. Adropin levels are significantly reduced in obese and diabetic
human subjects, and this decrease is linked to increased adiposity and impaired glucose homeostasis.
Furthermore, adropin depletion has been linked with the development of liver-associated obesity diseases
such as NAFLD and NASH. In this fellowship application, we will determine the molecular signaling pathways
underlying adropin function in liver fuel metabolism, and investigate its protective effects against NAFLD and
NASH. In Aim 1, we will determine how adropin associates with the cell membrane receptor GPR19 to regulate
hepatocyte fuel metabolism. In Aim 2, we will determine if GPR19 is necessary for the protective effects of
adropin against hepatic injury. By combining cutting-edge metabolic techniques and a comprehensive training
plan, this fellowship will allow me to prepare for the next stage of my career in metabolic research and scientific
education.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
海外基金